18:53 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Biogen, Eisai's elenbecestat reduces plaques, slows AD progression in Phase II

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) reported data from the Phase II Study 202 for their β-site APP-cleaving enzyme 1 (BACE1) inhibitor elenbecestat (E2609) showing that the therapy reduced amyloid plaques and slowed...
16:50 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Biogen, Eisai's BAN2401 slows cognitive decline by 30% in Phase II Alzheimer's trial

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented highly anticipated detailed results for BAN2401 at the Alzheimer's Association International Conference showing that the anti-β-amyloid therapy slowed cognitive decline by as much as 30%. However,...
21:56 , Jul 26, 2018 |  BC Extra  |  Company News

Biogen, Eisai AD readout leads to stock dive

Biogen Inc. (NASDAQ:BIIB) sank $39.09 (10%) to $344.74 on Thursday after reporting detailed data from a Phase II trial of Alzheimer's disease candidate BAN2401. Although the data showed that the anti-β amyloid therapy slowed cognitive...
23:50 , Jul 25, 2018 |  BC Extra  |  Clinical News

BAN2401 slows cognitive decline by 30% in Phase II Alzheimer's trial

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented highly anticipated detailed results for BAN2401 Wednesday at the Alzheimer's Association International Conference showing that the anti-β amyloid therapy slowed cognitive decline by as much as...
16:16 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Biogen, Eisai's BAN2401 slows AD progression at 18 months

Biogen Inc. (NASDAQ:BIIB) and partner Eisai Co. Ltd. (Tokyo:4523) reported secondary endpoint data on July 5 showing that the highest dose of BAN2401 significantly slowed disease progression and reduced beta amyloid at 18 months in...
23:25 , Jul 6, 2018 |  BC Extra  |  Financial News

Biotech stocks rise after positive AD data

Biotech indexes gained Friday after Biogen Inc. (NASDAQ:BIIB) and Eisai Co. Ltd. (Tokyo:4523) reported 18-month data for BAN2401 to treat Alzheimer's disease. Biogen gained $58.67 (20%) to $357.48, adding about $12.3 billion in market cap,...
03:32 , Jul 6, 2018 |  BC Extra  |  Clinical News

BAN2401 slows AD progression at 18 months

Biogen Inc. (NASDAQ:BIIB) gained $58.67 (20%) to $357.48 on Friday, adding about $12.3 billion in market cap, on new data for its Alzheimer's disease candidate BAN2401. Biogen and partner Eisai Co. Ltd. (Tokyo:4523) reported secondary...
17:04 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

Eisai, Biogen continuing AD trial of BAN2401 despite 12-month failure

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) said an IDMC determined that BAN2401 "did not meet the criteria for success" at 12 months on the primary endpoint in the Phase II Study 201 to...
21:43 , Dec 21, 2017 |  BC Extra  |  Clinical News

Eisai, Biogen continuing AD trial despite 12-month failure

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) said an IDMC determined that BAN2401 "did not meet the criteria for success" at 12 months on the primary endpoint in the Phase II Study 201 to...
02:00 , Oct 28, 2017 |  BioCentury  |  Strategy

Biogen doubles down

Shares of Biogen Inc. were buffeted last week by a pair of poorly understood moves intended to improve the big biotech’s share of profits for aducanumab, along with lower than expected revenues for newly launched...